hI-con1

a chimeric protein that targets tissue factor; consists of two proteins of human fVII fused to human IgG1 Fc with the two proteins joined by disulfide bonds

Networked: 4 relevant articles (3 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Azodi, Masoud: 2 articles (10/2011 - 06/2011)
2.	Bellone, Marta: 2 articles (10/2011 - 06/2011)
3.	Bellone, Stefania: 2 articles (10/2011 - 06/2011)
4.	Buza, Natalia: 2 articles (10/2011 - 06/2011)
5.	Carrara, Luisa: 2 articles (10/2011 - 06/2011)
6.	Cocco, Emiliano: 2 articles (10/2011 - 06/2011)
7.	Lockwood, Charles J: 2 articles (10/2011 - 06/2011)
8.	Pecorelli, Sergio: 2 articles (10/2011 - 06/2011)
9.	Rutherford, Thomas J: 2 articles (10/2011 - 06/2011)
10.	Santin, Alessandro D: 2 articles (10/2011 - 06/2011)

Related Diseases

1.	Choroidal Neovascularization 01/01/2017 - "To compare the efficacy of microneedle-delivered suprachoroidal (SC) pazopanib to intravitreal (Ivit) delivery of pazopanib, bevacizumab, or a fusion protein hI-con1 versus vehicle controls on choroidal neovascularization (CNV) growth in a pig model. "
2.	Ovarian Neoplasms (Ovarian Cancer) 10/01/2011 - "hI-con1 molecule induces strong cytotoxicity against primary chemotherapy-resistant ovarian cancer cell lines overexpressing TF and may represent a novel therapeutic agent for the treatment of ovarian tumors refractory to standard treatment modalities." 10/01/2011 - "We evaluated the expression of tissue factor (TF) in ovarian cancer (EOC) and the potential of hI-con1, an antibody-like molecule targeting TF, as a novel form of therapy against chemotherapy-resistant ovarian disease. " 10/01/2011 - "Tissue factor expression in ovarian cancer: implications for immunotherapy with hI-con1, a factor VII-IgGF(c) chimeric protein targeting tissue factor."
3.	Neoplasms (Cancer) 10/01/2011 - "hI-con1 molecule induces strong cytotoxicity against primary chemotherapy-resistant ovarian cancer cell lines overexpressing TF and may represent a novel therapeutic agent for the treatment of ovarian tumors refractory to standard treatment modalities."
4.	Uterine Cervical Neoplasms (Cancer of the Cervix) 06/22/2011 - "hI-con1 induces strong cytotoxicity against primary cervical cancer cell lines overexpressing TF and may represent a novel therapeutic agent for the treatment of cervical cancer refractory to standard treatment modalities." 06/22/2011 - "Low doses of interleukin-2 further increased the cytotoxic effect induced by hI-con1 (p=0.025) while human serum did not significantly decrease IDCC against cervical cancer cell lines (p=0.597). " 06/22/2011 - "All primary cervical cancer cell lines tested overexpressing TF, regardless of their histology, were highly sensitive to IDCC (mean killing±SD, 56.2%±15.9%, range, 32.4%-76.9%, p<0.001), while negligible cytotoxicity was seen in the absence of hI-con1 or in the presence of rituximab-control-antibody. " 06/22/2011 - "We evaluated the expression of Tissue Factor (TF) in cervical cancer and the potential of hI-con1, an antibody-like-molecule targeted against TF, as a novel form of immunotherapy against multiple primary cervical carcinoma cell lines with squamous- and adenocarcinoma histology. "
5.	Ovarian Diseases (Ovarian Disease) 10/01/2011 - "We evaluated the expression of tissue factor (TF) in ovarian cancer (EOC) and the potential of hI-con1, an antibody-like molecule targeting TF, as a novel form of therapy against chemotherapy-resistant ovarian disease. "

Related Drugs and Biologics

1.	Proteins (Proteins, Gene)
2.	Bevacizumab (Avastin)
3.	pazopanib
4.	Thromboplastin (Tissue Factor)
5.	A-factor (Streptomyces)
6.	Rituximab (Mabthera)
7.	Interleukin-2 (IL2)

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Immunotherapy
3.	Therapeutics